MCI-154, a Ca2+ sensitizer, increases survival in cardiomyopathic hamsters
| Autor: | Akira Ishibashi, Yuji Abe, Hisashi Kawasumi, Yoshimi Kitada |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Male
medicine.medical_specialty Cardiotonic Agents Heart disease medicine.medical_treatment Cardiomyopathy Hamster Cumulative survival behavioral disciplines and activities Oral administration Cricetinae Internal medicine mental disorders Animals Medicine Survival rate Pharmacology Chemotherapy Mesocricetus business.industry medicine.disease nervous system diseases Pyridazines Disease Models Animal Endocrinology Heart failure Calcium Cardiomyopathies business human activities |
| Zdroj: | European Journal of Pharmacology. 372:175-178 |
| ISSN: | 0014-2999 |
| DOI: | 10.1016/s0014-2999(99)00204-6 |
| Popis: | To assess the long-term efficacy of a Ca2+ sensitizer MCI-154, 6-[4-(4'-pyridylamino)phenyl]-4,5-dihydro-3(2H)-pyridazinone hydrochloride trihydrate, on chronic heart failure, we studied the effects of the agent on the life span of cardiomyopathic hamsters of the BIO-14.6 strain. At approximately 150 days of age, 210 male hamsters were randomly divided into three groups: MCI-154 0.1 mg kg(-1), day(-1)(MCI-154-low), MCI-154 1 mg kg(-1) day(-1) (MCI-154-high), and control group. The median survival time in control, MCI-154-low and MCI-154-high groups was 227, 243 and 260 days after the start of treatment, respectively. Final survival rate at 284 days in control, MCI-154-low and MCI-154-high groups was 0, 17.1 and 38.6%, respectively. The cumulative survival times in the two MCI-154 treated groups were significantly prolonged in comparison with that in the control group (P0.0001). Thus, the present study clearly showed that MCI-154 prolonged the life span of cardiomyopathic hamsters, suggesting that long-term therapy with MCI-154 would be promising in the treatment of congestive heart failure. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect